Retrophin, Inc. (NASDAQ:RTRX) Q2 2020 Earnings Conference Call - Final Transcript

Jul 30, 2020 • 04:30 pm ET


Retrophin, Inc. (NASDAQ:RTRX) Q2 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Ladies and gentlemen, thank you for standing by. I apologize for the delay, and welcome to the Retrophin, Inc. Second Quarter Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions]

I would now like to turn the call over to Mr. Chris Cline. Sir, please go ahead.

Chris Cline

Great. Thank you, Corey. Good afternoon, and welcome to Retrophin's Second Quarter 2020 Financial Results and Corporate Update Call. Thank you for joining us today, and thank you for sticking with us through some of the technical difficulties we were just experiencing. I hope you all remain well.

Today's call will be led by our Chief Executive Officer, Dr. Eric Dube. Eric will be joined for the prepared remarks by our Chief Medical Officer, Dr. Noah Rosenberg; Peter Heerma, our Chief Commercial Officer; and our Chief Financial Officer, Laura Clague. Dr. Bill Rote, Senior Vice President of Research and Development, will join us for the Q&A session.

Before we begin, I'd like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, performance and achievements to differ materially from those expressed or implied by the statement. Please see the forward-looking statement disclaimer on the Company's press release issued earlier today as well as the Risk Factors section in our forms 10-Q and 10-K filed with the SEC. In addition, any forward-looking statements represent our views only as of the date such statements are made, July 30, 2020. And Retrophin specifically disclaims any obligation to update such statements to reflect future information, events or circumstances.

With that, let me now turn the call over to Eric. Eric?

Eric Dube

Thank you, Chris, and good afternoon, everyone. The needs of patients living with rare disease are greater than ever, and I am proud of our organization's steadfast dedication to supporting our communities, advancing our development programs and delivering our approved products during this difficult time. I am pleased to report that during the second quarter, our team members maintained focus on the key priorities to best navigate the COVID-19 pandemic and continue to make meaningful progress towards our goals for the year. This was highlighted by the further advancement of our two pivotal trials for sparsentan and the continued delivery of our approved therapies to current and new patients.

We were able to achieve this by maintaining a focus on the safety and well-being of our key members and our patients. For our team members, we continue to embrace a remote work environment, and I am incredibly impressed by how our teams come together every day on a virtual basis and identify innovative ways to advance our initiatives and meet the needs of our